Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer.
Full description
This is an open-label phase II multi-centre single arm study which proposes to test the anti-tumour efficacy of paricalcitol, in combination with GEM/Nab-paclitaxel in patients with advanced metastatic pancreatic cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Written informed consent obtained prior to any study-related procedures.
Incurable recurrent, locally advanced or metastatic pancreatic adenocarcinoma.
Histologically or cytologically confirmed pancreatic adenocarcinoma.
No prior chemotherapy for incurable, locally advanced unresectable or metastatic pancreatic cancer. Patients may have received prior chemotherapy in the neo-adjuvant or adjuvant setting provided they have a minimum treatment-free interval of 3 months.
At least one measurable lesion according to RECIST criteria (Version 1.1). Patients with bone only disease are not eligible.
Aged 18 years or older
ECOG performance status 0 - 2
Adequate haematological, renal and hepatic function measured within 28 days prior to commencing study:
Total bilirubin ≤ ULN (or ≤ 3 x ULN (≤ grade 2) for patients with liver involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN (≤ grade
Glomerular filtration rate (GFR) ≥ 30mL/min/1.73 m2 (≤ grade 2) for patients with serum creatinine levels above or below the institutional normal range. If using creatinine clearance, actual body weight should be used for calculating creatinine clearance (e.g., using the Cockroft-Gault formula). For patients with a Body Mass Index (BMI) >30 kg/m2, lean body weight should be used instead.
Platelet count ≥ 100 x 109/L.
Haemoglobin (Hb) ≥ 8 g/dL (≤ grade 2)
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (≤ grade 1)
Corrected serum calcium of ≤ 2.9 mmol/L (≤ grade 1).
Life expectancy of at least 12 weeks.
Women of childbearing potential and sexually active males must agree to use highly effective contraceptive measures. This applies from starting treatment until at least 6 months after the last study drug administration. The investigator or a designated associate is required to advise the patient how to achieve an adequate birth control. Highly effective contraception is defined in the study as methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include:
i. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal). ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable and implantable). iii. Intrauterine device (IUD). iv. Intrauterine hormone-releasing system (IUS). v. Bilateral tubal occlusion. vi. Successfully vasectomised partner. vii. Sexual abstinence.
Exclusion criteria
Treated with other investigational drugs within 28 days or 5.5 half-lives of treatment start; in addition, concurrent alternative (complementary) medications are excluded within 28 days of treatment start.
Known brain metastases, unless previously treated and well-controlled for at least 2 months.
Dementia, altered mental status, or any other psychiatric condition that would interfere with the patient's safety or informed consent
History of other malignancy other than pancreatic cancer. However, patients who have been disease free from another malignancy for at least 5 years, or patients with a history of resected non-melanoma skin cancer or successfully treated in situ cancer and superficial bladder tumours (Ta, Tis, T1) are eligible.
Known history of hypercalcaemia.
Presence or history of symptomatic kidney stones in the last 5 years.
Active, clinically serious infections > grade 2 (CTCAE v5.0).
Greater than or equal to grade 2 sensory or motor neuropathy
Uncontrolled intercurrent illness, including, but not limited to uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or social situation that would affect compliance with the requirements of this study.
GI tract disease resulting in an inability to take oral medications, malabsorption syndrome, where previous surgical procedures affect absorption and uncontrolled inflammatory bowel disease.
History of diseases known to be associated with calcium disorders, including: ongoing hyperparathyroidism and Sarcoidosis.
Hypersensitivity to any of the excipients of gemcitabine, Nab-paclitaxel or Paricalcitol.
Known vitamin D toxicity
Undergoing treatment with the following therapies and medications:
Note:
Primary purpose
Allocation
Interventional model
Masking
15 participants in 1 patient group
There are currently no registered sites for this trial.
Start date
Oct 16, 2020 • 4 years ago
End date
Sep 30, 2022 • 2 years ago
Today
Apr 02, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal